Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-08-18

Clinical Trial Results: Cardiac Allograft Vasculopathy Inhibition With Alirocumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alirocumab for inhibition of cardiac allograft vasculopathy; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • alirocumab (alirocumab)

Snippet

Sponsor: Stanford University | Conditions: Vasculopathy | Phase 2 | Status: COMPLETED | Results posted: 2026-08-18